In this piece, we will take a look at the ten best all-time low stocks to buy right now.

With November coming to a close, while markets are focused on the future of artificial intelligence and the degree of profitability that AI firms can extract from their multi-billion dollar investments, other factors are also driving investors’ decision-making. The non-AI factors dominating markets include inflation, economic growth, and the Federal Reserve’s interest rate reduction cycle.

In fact, even though AI has driven the narrative for markets in 2023 and 2024, before it, macroeconomic concerns were the primary factors behind investor decision-making. The US economy grappled with historic inflation following the lax monetary policy during the coronavirus pandemic. To tamp down inflation, the Federal Reserve hiked rates to two-decade-high levels.

Now, the macro narrative on Wall Street is driven by how fast the Fed will reduce interest rates. Higher rates and a tight economy have broad implications for stocks. They drive cyclical sectors to low levels and prop up others such as financials and defensives. Additionally, tighter discretionary spending means that high-growth sectors like electric vehicles suffer. High interest rates also constrain sectors such as real estate, while a sluggish economy leads to others such as industrial also lagging major stock indexes.

However, when discussing all-time low stocks, one has to keep in mind that their share price often drops not only because of broader sector and market-level trends but also because of microeconomic and firm-specific factors. To understand how microeconomic factors are nearly indispensable factors in driving these trends, consider the shares of one of the most well-known dating applications in the US and worldwide. This stock ranked fourth on our list of the best oversold tech stocks to buy as of late October. Its shares are down 40% year-to-date after having slightly recovered from the 54.14% drop at the time of our coverage.

Its stock tanked to an all-time low price of $5.71 the day after the firm released its second-quarter earnings report. Dating applications are a classic example of firms dependent on discretionary spending. For this firm, its earnings report saw Q2 revenue of $268.6 million miss analyst estimates of $273 million. While earnings-per-share of $0.22 did beat analyst estimates of $0.15, they merely reflected cost cutting. The broader slowdown in the dating application market, as evidenced by rival firm Tinder’s shares dropping by 17.8% in November after its third-quarter earnings is evidence of macroeconomic factors that push stocks toward all-time lows.

However, for the stock under discussion, micro and firm-specific factors also played a role in the stock touching the all-time low level.  The accompanying fiscal year revenue growth guidance in the second-quarter earnings is what was responsible for the historic 29% post-earnings share price drop. The firm guided full-year revenue growth to range between 1% and 2%, which was far lower than analyst estimates of 8.4% and the previous guidance of 8% to 11%. Consequently, investors reacted and priced out the over-stretched growth estimates from the share price.

These growth estimates were based on firm-specific factors, which as we’ve pointed out above, are key to push any stock to new lows. This strategy has seen it revamp its dating application and seek to bolster revenue by focusing on the Premium Plus segment. However, the ill-fated earnings report saw it announce the decision to “slow down certain monetization efforts like Premium Plus.” As per management, the decision stemmed from a need to re-balance “subscription tiers and merchandising in favor of mechanisms that reward positive peer behaviors and support better ecosystem health.” Naturally, a flip in much-touted growth initiatives at a time when revenue missed guidance and the industry had slowed down did not impress investors and they punished the stock in response.

Another stock that touched all-time lows in 2024 is the well-known firm that owns CNN and other media assets. Formed after WarnerMedia’s spin-off and subsequent merger with Discovery, the shares touched $6.71 in August for their lowest reading following the merger in 2022. As was the case with the dating application’s stock, macro and micro factors had a role to play. The firm’s second-quarter earnings saw it report a whopping $10 billion loss and miss analyst revenue estimates of $10.07 by posting $9.71 in revenue.

However, while the earnings report wasn’t stellar, the true reason behind the drop was the television network division. The firm’s earnings report saw it write down its media asset value by an unbelievable $9.1 billion which indicated to investors that it had overpaid for them at the time of its merger. Naturally, Wall Street wasn’t impressed and the stock tumbled to a 15-year low if we analyze pre-merger share price performance as well.

Our Methodology

To make our list of the best all-time low stocks to buy, we made a list of 40 stocks with a market capitalization greater than $300 million that were trading at ranges 0% to 10% above their all-time low price. These stocks were ranked by the number of hedge fund investors that had bought the shares during Q3 2024, and those with the highest number of investors were chosen.

Why are we interested in stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).

10. BioAge Labs, Inc. (NASDAQ:BIOA)

Number of Hedge Fund Holders In Q3 2024: 17

BioAge Labs, Inc. (NASDAQ:BIOA) is a pre-revenue biotechnology company headquartered in Richmond, California. The firm is seeking to capitalize on the weight loss drug market, with its leading product being azelaprag. BioAge Labs, Inc. (NASDAQ:BIOA) aims to use azelaprag to work with Eli Lilly’s Tirzapetide to help patients seeking to lose weight. This drug is currently in phase two trials, and BioAge Labs, Inc. (NASDAQ:BIOA) expects to release data in the third quarter of 2025. Consequently, the stock is quite risky, as any delay in data release will translate poorly for the shares. BioAge Labs, Inc. (NASDAQ:BIOA)’s inability to generate revenue places all of its eggs in one basket, but the firm benefits from its partnership with Lilly which has helped design azelaprag’s trial plans.

9. ABIVAX Société Anonyme (NASDAQ:ABVX)

Number of Hedge Fund Holders In Q3 2024: 17

ABIVAX Société Anonyme (NASDAQ:ABVX) is another pre-revenue stage biotechnology firm. It is based in France and aims to treat ulcerative colitis by manipulating the human body’s immune system response. ABIVAX Société Anonyme (NASDAQ:ABVX)’s hypothesis depends entirely on its leading drug candidate for colitis called obefazimod. Fortunately for those bullish on the stock, obefazimod is currently in Phase 2 trials which removes a lot of uncertainty from its future. October was an important month for ABIVAX Société Anonyme (NASDAQ:ABVX)’s drug as the firm announced interim efficacy results of the drug and enrolled the first participant in a trial for Crohn’s disease. The efficacy results showed disease remission and sent ABIVAX Société Anonyme (NASDAQ:ABVX)’s European shares up by 3.1%.